thymic extract is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-02-21. Numbers and descriptions here follow the published literature rather than marketing material.
Immune signaling studies link thymosin alpha 1 to Toll-like receptor pathways, particularly TLR2 and TLR9, on dendritic cells and other antigen-presenting cells. Activation of these receptors promotes maturation of T cells and increases natural killer cell activity. The peptide shifts cytokine output toward a T helper 1 profile, raising interferon gamma and interleukin 2 while modulating interleukin 10. Whether these effects translate into clinical benefit for any specific disease remains a subject of debate. Reported outcomes vary across trials and populations.
Thymosin alpha 1 is approved as a medicine in several countries, including Italy and China, for indications such as chronic hepatitis B and as an immune adjuvant. It is not approved by the United States Food and Drug Administration as a therapeutic product. In research settings the peptide appears in studies of sepsis, vaccine response, and oncology support, often with mixed or inconclusive results. The evidence base is uneven, and reviews note that many trials were small. Regulatory status therefore differs widely between jurisdictions.
Thymosin alpha 1 is a 28-amino-acid peptide first isolated from thymosin fraction 5, a bovine thymic extract. Its sequence begins with an acetylated serine residue and carries a high proportion of acidic residues, so the molecule has a net negative charge near neutral pH. Despite the shared name, it is unrelated in sequence to the thymosin beta family. Synthetic material prepared by solid-phase peptide synthesis is identical in sequence to the natural peptide.
Several names appear in the literature for this peptide, including thymalfasin and the abbreviation T-alpha-1. Naming conventions differ among research articles, regulatory documents, and supplier catalogs, which complicates literature searches. Both synthetic and recombinant production routes yield a peptide with the same 28-residue sequence as the thymic isolate. Because the thymosin label also covers unrelated peptides, sources should be compared by sequence rather than by name alone.
The peptide occurs naturally in thymic tissue and has been detected in serum and other biological fluids. Reported concentrations are low, and reliable measurement generally requires immunoassay or mass spectrometry with an enrichment step. It is released from a larger precursor, prothymosin alpha, by proteolytic cleavage, although the enzymes involved are not fully characterized. Whether circulating levels reflect thymic output specifically remains an open question.
| Property | Value | Notes |
|---|---|---|
| Molecular mass | ≈3,108 Da | Synthetic 28-residue peptide |
| Amino acid count | 28 | N-terminal serine carries an acetyl group |
| Appearance | White to off-white powder | Lyophilized solid |
| Water solubility | Freely soluble | Dissolves in aqueous buffer |
| Common synonyms | Thymalfasin; Tα1 | Thymalfasin is the international nonproprietary name |
By contrast, K-selected species display traits associated with living at densities close to carrying capacity, and typically are strong competitors in such crowded niches that invest more heavily in fewer offspring, each of which has a relatively high probability of surviving to adulthood (i.e., low r, high K). Between these two extremes, the American kestrel is one of the few raptor species that lean towards being r-selected. They are able to breed at one year old, have few non-breeding adults in the population, and have larger broods. Their population growth rate is high relative to larger raptors, which typically lean towards being K-selected. This said, older American kestrel pairs generally have larger brood sizes and produce more viable offspring than younger conspecifics.
Gearbox announced the formation of Gearbox Studios as a third company under the Gearbox Entertainment Company on October 6, 2021, to oversee television and film productions, with Pitchford serving as Gearbox Studios president alongside as president and CEO of the parent company. Former CTO Steve Jones was named as president of Gearbox Software in Pitchford's place. Embracer announced it intent to acquire Perfect World Entertainment in December 2021 and placing the group, including its publishing arm and Cryptic Studios, under the Gearbox Entertainment operating group. Following its acquisition in April 2022, Perfect World Entertainment was rebranded as Gearbox Publishing San Francisco, with the naming to be applied retroactively to past games published under Perfect World. In April 2022, Gearbox Entertainment announced it will acquire Lost Boys Interactive, which had supported Gearbox in Tiny Tina's Wonderlands. Later that November, Gearbox acquired the Risk of Rain IP from Hopoo Games, while Embracer transferred ownership of Volition to Gearbox Entertainment from Deep Silver following poor reception to its Saints Row reboot. The studio would later shut down the following year due to the restructuring of Embracer Group. That same month, Eidos Shanghai, another studio under the Embracer Group, was transferred to Gearbox Publishing San Francisco and rebranded as Gearbox Studio Shanghai. Gearbox Entertainment acquired Captured Dimensions, a 3D modeling company from Texas, in January 2023.
=== Other transplants and induced regeneration === There is ongoing research and development into synthetic biology based methods for inducing regeneration in humans as well the creation of transplantable artificial organs.
Sources: en.wikipedia.org
=== Pharmacokinetics === The time to peak concentrations following a dose is 2 to 4 hours. The typical antidepressant therapeutic range of trimipramine concentrations is 150 to 300 ng/mL. The terminal half-life of trimipramine has been variously reported to be as little as 8 hours (in plasma) and as long as 24 hours. In any case, the terminal half-life of trimipramine is described as shorter than that of other TCAs, which makes it ideal for use in the treatment of insomnia. Trimipramine is a racemic compound with two enantiomers.[1] CYP2C19 is responsible for the demethylation of (D)- and (L)-trimipramine to (D)- (L)-desmethyltrimipramine, respectively, and CYP2D6 is responsible for the 2-hydroxylation of (D)- and (L)-desmethyltrimipramine to (D)- and (L)-2-hydroxydesmethyltrimipramine, respectively. CYP2D6 also metabolizes (L)-trimipramine into (L)-2-hydroxytrimipramine.
In addition to these biomarkers, the FDA has approved certain drug-companion diagnostic pairings based on genetic mutations. For example, BRAF-targeted therapies for metastatic melanoma are only indicated for patients whose tumors harbor a BRAF mutation. While these tests are now commonly marketed as essential tools for precision oncology, they remain costly. Moreover, some have been the subject of controversy or misuse. Notable examples include the Duke University cancer fraud scandal and questionable claims surrounding so-called "liquid biopsies."
The timber of living trees and fresh logs contains a large amount of water which often constitutes over 50% of the wood's weight. Water has a significant influence on wood. Wood continually exchanges moisture or water with its surroundings, although the rate of exchange is strongly affected by the degree to which wood is sealed. Wood contains water in three forms:
Sources: en.wikipedia.org
In addition to writing fiction, Tolkien was an author of academic literary criticism. His seminal 1936 lecture, later published as an article, revolutionized the treatment of the Anglo-Saxon epic Beowulf by literary critics. The essay remains highly influential in the study of Old English literature to this day. Beowulf is one of the most significant influences upon Tolkien's later fiction, with major details of both The Hobbit and The Lord of the Rings being adapted from the poem.
Irwin Douglas "Tack" Kuntz is an important figure in the field of computer-aided drug design and molecular modeling. He is a pioneer in the development and conception of the area of study known as molecular docking. One of the first docking programs DOCK was developed in his group in 1982.
Unsuccessful treatment procedure which can lead to recurrent defect Post-treatment infection Barrier membrane being worn away, caused by e.g. traumatic toothbrushing Vitality of tooth being compromised in furcation-involved teeth Unfavourable gingival adaptation which can be of aesthetic concern Dentine hypersensitivity Requirement for long term professional maintenance
Sources: en.wikipedia.org
It is a chain of 28 amino acids, with an acetyl group attached to the first serine residue. The synthetic version replicates this sequence. Its molecular mass is about 3,108 daltons.
It is usually described as an immunomodulatory peptide rather than a classic hormone. It acts on immune cells through receptor pathways. No single endocrine organ target defines its function.
Several countries, including Italy and China, allow it for specific indications. The FDA has not approved it as a drug in the United States. Availability depends on local regulation.
It is a 28-amino-acid peptide originally purified from a bovine thymic extract and later produced synthetically. It is studied mainly for its effects on immune cell function.